SCHEMBL711684

SCHEMBL711684

Nc1nc(Nc2ccc(S(=O)(=O)Nc3nccs3)cc2)nn1Cc1ccc(Cl)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
SCN9A Q15858 4/20 0.54
SCN3A Q9NY46 4/20 0.54
SCN5A Q14524 1/20 0.54
PPIA P62937 1/20 0.53
CCNT1 O60563 2/20 0.51
CDK9 P50750 2/20 0.51
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
CYP2C9 P11712 1/20 0.49
EDNRA P25101 1/20 0.49
SLC6A4 P31645 1/20 0.49
ADRA1A P35348 1/20 0.49
PRMT6 Q96LA8 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
ALOX12 P18054 1/20 0.48
AVPR2 P30518 1/20 0.46
GPR27 Q9NS67 1/20 0.46
MEN1 O00255 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714461 0.80 LMNA (0.57) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL711578 0.78 ALDH1A1 (0.54) LMNASMN1; SMN2PPIACCNT1CDK9
SCHEMBL712663 0.75 LMNA (0.62) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL712892 0.73 SCN9A (0.63) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL713144 0.73 SCN9A (0.53) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL712587 0.73 LMNA (0.62) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL714319 0.73 LMNA (0.58) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL712534 0.73 SCN9A (0.54) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL713988 0.73 ALDH1A1 (0.64) LMNASMN1; SMN2SCN9ASCN3ASCN5A
SCHEMBL31272007 0.73 MAPT (0.47) LMNASMN1; SMN2KDM4EALDH1A1ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US claimed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
US-8124610-B2 Sodium channel inhibitors ICAGEN INC. (US) 2012-02-28 US disclosed
EP-2173743-A2 SODIUM CHANNEL INHIBITORS Icagen, Inc. (US) 2010-04-14 EP disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed
WO-2009012242-A2 SODIUM CHANNEL INHIBITORS ICAGEN, INC. (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A LMNA 2921/4885SMN1; SMN2 287/4885SCN9A 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.